Filana Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Filana Therapeutics, Inc. (FLNA) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$867.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-05-07
- Filana Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$867.00K.
- Filana Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$952.00K.
- Filana Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $390.00K.
- Filana Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-06-30 was -$383.00K, a 107.66% decline year-over-year.
- Filana Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$6.08M.
- Filana Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$539.00K.
- Filana Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$1.71M.
- Filana Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$1.19M, a 110.85% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$867.00K 10-Q · filed 2026-05-07 | -$1.82M derived: sum of 2 quarters · filed 2026-05-07 | -$1.43M derived: sum of 3 quarters · filed 2026-05-07 | -$1.81M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | -$952.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$562.00K derived: sum of 2 quarters · filed 2026-03-12 | -$945.00K derived: sum of 3 quarters · filed 2026-03-12 | -$6.08M 10-K · filed 2026-03-12 |
| 2025-09-30 | $390.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $7.00K derived: sum of 2 quarters · filed 2025-11-12 | -$5.13M 10-Q · filed 2025-11-12 | -$10.74M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-06-30 | -$383.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$5.52M 10-Q · filed 2025-08-14 | -$11.13M derived: sum of 3 quarters · filed 2026-05-07 | -$12.39M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-03-31 | -$5.13M 10-Q · filed 2026-05-07 | -$10.75M derived: sum of 2 quarters · filed 2026-05-07 | -$12.01M derived: sum of 3 quarters · filed 2026-05-07 | -$7.01M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$5.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$6.87M derived: sum of 2 quarters · filed 2026-03-12 | -$1.87M derived: sum of 3 quarters · filed 2026-03-12 | -$539.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | -$1.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.74M derived: sum of 2 quarters · filed 2025-11-12 | $5.07M 10-Q · filed 2025-11-12 | $5.74M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $6.33M 10-Q · filed 2025-08-14 | $7.00M derived: sum of 3 quarters · filed 2026-03-12 | $8.74M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $1.33M 10-Q · filed 2025-05-08 | $2.00M derived: sum of 2 quarters · filed 2026-03-12 | $3.73M derived: sum of 3 quarters · filed 2026-03-12 | $2.30M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $663.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.40M derived: sum of 2 quarters · filed 2026-03-12 | $965.00K derived: sum of 3 quarters · filed 2026-03-12 | -$1.71M 10-K · filed 2026-03-12 |
| 2023-09-30 | $1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $302.00K derived: sum of 2 quarters · filed 2024-11-07 | -$2.38M 10-Q · filed 2024-11-07 | -$776.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$4.12M 10-Q · filed 2024-08-08 | -$2.52M derived: sum of 3 quarters · filed 2025-03-03 | -$874.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$2.68M 10-Q · filed 2024-05-10 | -$1.08M derived: sum of 2 quarters · filed 2025-03-03 | $563.00K derived: sum of 3 quarters · filed 2025-03-03 | -$4.93M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $3.24M derived: sum of 2 quarters · filed 2025-03-03 | -$2.25M derived: sum of 3 quarters · filed 2025-03-03 | -$1.19M 10-K · filed 2025-03-03 |
| 2022-09-30 | $1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$3.85M derived: sum of 2 quarters · filed 2023-11-07 | -$2.79M 10-Q · filed 2023-11-07 | -$1.94M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$5.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$4.43M 10-Q · filed 2023-08-03 | -$3.58M derived: sum of 3 quarters · filed 2024-02-28 | $4.29M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $1.06M 10-Q · filed 2023-05-01 | $1.92M derived: sum of 2 quarters · filed 2024-02-28 | $9.78M derived: sum of 3 quarters · filed 2024-02-28 | $12.20M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $854.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $8.72M derived: sum of 2 quarters · filed 2024-02-28 | $11.14M derived: sum of 3 quarters · filed 2024-02-28 | $10.96M 10-K · filed 2024-02-28 |
| 2021-09-30 | $7.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $10.29M derived: sum of 2 quarters · filed 2022-11-07 | $10.10M 10-Q · filed 2022-11-07 | $9.59M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $2.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $2.24M 10-Q · filed 2022-08-04 | $1.73M derived: sum of 3 quarters · filed 2023-02-28 | $2.54M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$185.00K 10-Q · filed 2022-05-05 | -$694.00K derived: sum of 2 quarters · filed 2023-02-28 | $117.00K derived: sum of 3 quarters · filed 2023-02-28 | |
| 2020-12-31 | -$509.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $302.00K derived: sum of 2 quarters · filed 2023-02-28 | $220.00K 10-K · filed 2023-02-28 | |
| 2020-09-30 | $811.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $729.00K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | -$82.00K 10-Q · filed 2021-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |